Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2021.105137 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2021.105137 34265358!8274277!34265358     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antiviral+Res 2021 ; 193 (ä): 105137 Nephropedia Template TP {{tp|p=34265358|t=2021. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 |pdf=|usr=}}{{34265358}} gab.com Text Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=34265358 #FOAvip Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of imatinib in multiple models. Our results indicated that imatinib and another TKI, the masitinib, exhibit an antiviral activity in VeroE6 cells. However, imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of imatinib and similar TKIs as antivirals in the treatment of Covid-19. Twit Text FOAVip Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=34265358 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34265358 #FOAvip English Wikipedia <ref>{{Cite pmid|34265358}}</ref> Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 #MMPMID34265358 Touret F; Driouich JS; Cochin M; Petit PR; Gilles M; Barthelemy K; Moureau G; Mahon FX; Malvy D; Solas C; de Lamballerie X; Nougairede A Antiviral Res 2021[Sep]; 193 (ä): 105137 PMID34265358show ga Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of imatinib in multiple models. Our results indicated that imatinib and another TKI, the masitinib, exhibit an antiviral activity in VeroE6 cells. However, imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of imatinib and similar TKIs as antivirals in the treatment of Covid-19. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19/epidemiology/virology[MESH] |Cell Line[MESH] |Chlorocebus aethiops[MESH] |Drug Evaluation, Preclinical[MESH] |Drug Repositioning[MESH] |Enzyme Inhibitors/pharmacology[MESH] |Epithelium[MESH] |Female[MESH] |Humans[MESH] |Imatinib Mesylate/*pharmacology[MESH] |Lung/pathology[MESH] |Male[MESH] |Mesocricetus[MESH] |SARS-CoV-2/*drug effects[MESH] |Vero Cells[MESH]Preclinical evaluation of Imatinib does not support its use as an anti(epmc).pdf DeepDyve Pubget Overpricing